Planned omalizumab discontinuation in CSU management as a sustainable strategy: A 2-year real-life study

Allergy. 2020 Oct;75(10):2681-2684. doi: 10.1111/all.14341. Epub 2020 May 25.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anti-Allergic Agents* / therapeutic use
  • Chronic Disease
  • Humans
  • Omalizumab / therapeutic use
  • Treatment Outcome
  • Urticaria* / drug therapy

Substances

  • Anti-Allergic Agents
  • Omalizumab